Ponvory FDA Approval History
Last updated by Judith Stewart, BPharm on April 6, 2021.
Ponvory (ponesimod) is a selective sphingosine-1-phosphate receptor 1 (S1P1) modulator indicated for the treatment of adults with relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.
- Ponvory is thought to work by keeping lymphocytes out of the blood by trapping them in the lymph nodes. It may work in MS by reducing lymphocyte migration into the central nervous system.
- Ponvory is taken orally once daily, with gradual titration to a maintenance dose.
- Common adverse reactions include upper respiratory tract infection, hepatic transaminase elevation, and hypertension.
Development timeline for Ponvory
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.